{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:23:50Z","timestamp":1720657430965},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"DOI":"10.7759\/cureus.64191","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:39:55Z","timestamp":1720582795000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-melanoma Differentiation-Associated Gene 5 (Anti-MDA5) Dermatomyositis-Associated Interstitial Lung Disease Complicated by Pneumomediastinum: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Shivang","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amulya","family":"Balagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson M","year":"2022","unstructured":"McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum. 2022, 53:10.1016\/j.semarthrit.2022.151959","journal-title":"Semin Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato S","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, et al.. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005, 52:1571-6. 10.1002\/art.21023","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman DJ","year":"2018","unstructured":"Kurtzman DJ, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018, 78:776-85. 10.1016\/j.jaad.2017.12.010","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer RD","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002, 46:626-36. 10.1067\/mjd.2002.120621","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino D","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011, 65:25-34. 10.1016\/j.jaad.2010.09.016","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1009546","article-title":"Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: time to nip them in the bud","volume":"13","author":"Yang J","year":"2022","unstructured":"Yang J, Yan B. Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: time to nip them in the bud. Front Immunol. 2022, 13:10.3389\/fimmu.2022.1009546","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji H","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, et al.. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020, 72:488-98. 10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen Z","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019, 381:291-3. 10.1056\/NEJMc1900045","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.820163","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","volume":"12","author":"He C","year":"2021","unstructured":"He C, Li W, Xie Q, Yin G. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review. Front Immunol. 2021, 12:10.3389\/fimmu.2021.820163","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.610554","article-title":"Case report: treatment of anti-MDA5-positive amyopathic dermatomyositis accompanied by a rapidly progressive interstitial lung diseases with methylprednisolone pulse therapy combined with cyclosporine A and hydroxychloroquine","volume":"7","author":"Zhang QC","year":"2020","unstructured":"Zhang QC, Liu MY, Chen ZX, Chen YT, Lin CS, Xu Q. Case report: treatment of anti-MDA5-positive amyopathic dermatomyositis accompanied by a rapidly progressive interstitial lung diseases with methylprednisolone pulse therapy combined with cyclosporine A and hydroxychloroquine. Front Med (Lausanne). 2020, 7:10.3389\/fmed.2020.610554","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima R","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016, 25:925-33. 10.1177\/0961203316651748","journal-title":"Lupus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01705-8","article-title":"Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients","volume":"16","author":"Yang Q","year":"2021","unstructured":"Yang Q, Li T, Zhang X, et al.. Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients. Orphanet J Rare Dis. 2021, 16:10.1186\/s13023-021-01705-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omae061","article-title":"Two challenging cases of anti-MDA-5 dermatomyositis with rapidly progressive interstitial lung disease","volume":"2024","author":"Biddle K","year":"2024","unstructured":"Biddle K, Agaoglu E, Brent G, et al.. Two challenging cases of anti-MDA-5 dermatomyositis with rapidly progressive interstitial lung disease. Oxf Med Case Reports. 2024, 2024:10.1093\/omcr\/omae061","journal-title":"Oxf Med Case Reports"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264814-anti-melanoma-differentiation-associated-gene-5-anti-mda5-dermatomyositis-associated-interstitial-lung-disease-complicated-by-pneumomediastinum-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:39:59Z","timestamp":1720582799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264814-anti-melanoma-differentiation-associated-gene-5-anti-mda5-dermatomyositis-associated-interstitial-lung-disease-complicated-by-pneumomediastinum-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.64191","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}